

CARCINOMES NASOPHARYNGES

ANTI PD1 MONOTHERAPIE

PATIENTS PRE TRAITES PAR PLATINE

PHASE III KN 122 Chan et al., ESMO 2021

53^e CONGRÈS
SFCCF 2021



Baseline Characteristics


	Pembro n = 117	Chemo n = 116		Pembro n = 117	Chemo n = 116
Age, median (range), years	51.0 (21-76)	51.0 (21-76)	Overall cancer stage, n (%)		
Male, n (%)	86 (83.8)	85 (81.9)	IV	114 (97.4)	112 (97.4)
Region, n (%)			Metastasis stage, n (%)		
North America	22 (18.8)	11 (9.5)	M0	12 (10.3)	10 (8.5)
Asia	85 (81.2)	105 (91.0)	M1	105 (99.7)	108 (91.4)
ECOG PS 1, n (%)	81 (69.2)	77 (66.4)	Presence of liver metastasis, n (%)	57 (48.7)	56 (48.3)
PD-L1, n (%)			Prior radiation, n (%)	103 (88.0)	95 (81.9)
CPG <10	54 (46.2)	52 (52.4)	Prior therapy with curative intent, ¹ n (%)	17 (14.5)	14 (12.1)
CPG ≥10	55 (47.0)	46 (39.7)	Prior lines of therapy, n (%)		
Missing	8 (6.8)	8 (6.8)	1	57 (48.2)	47 (41.1)
Disease status, n (%)			2	28 (23.9)	24 (20.7)
Recurrent	12 (10.3)	10 (9.6)	3	11 (9.4)	18 (15.5)
Metastatic	41 (35.0)	29 (25.0)	4	3 (2.6)	10 (8.5)
Recurrent and metastatic	84 (84.7)	77 (68.4)	≥5	4 (3.4)	4 (3.4)
Current or former smoker, n (%)	59 (50.4)	58 (50.0)			

CARCINOMES NASOPHARYNGES ANTI PD1 MONOTHERAPIE PATIENTS PRE TRAITES PAR PLATINE PHASE III KN 122 Chan et al., ESMO 2021


53^e CONGRÈS
SFCCF 2021



Overall Survival (ITT)



PFS per RECIST v1.1 by BICR (ITT)




CARCINOMES NASOPHARYNGES ANTI PD1 MONOTHERAPIE PATIENTS PRE TRAITES PAR PLATINE PHASE III KN 122 Chan et al., ESMO 2021

53^e CONGRES
SFCCF 2021




Best Overall Response and DOR^a

	Pembrolizumab n=117	Cisplatin n=118
ORR (95% CI)	24 (20.5-27.6)	23 (19.5-27.0)
DOR (95% CI)	20 (17.0-23.0)	21 (18.0-24.0)
Best Overall Response		
CR	1 (0.7%)	1 (0.8%)
PR	16 (13.7%)	15 (12.7%)
SD	24 (20.5%)	17 (14.4%)
PD	44 (37.5%)	28 (23.6%)
NC	2 (1.7%)	3 (2.5%)
NA	3 (2.5%)	14 (11.8%)
Time to next anti-PD1 median (range), mo	2.0 (1.2-2.0)	1.5 (1.2-1.5)



	Pembrolizumab n=117	Cisplatin n=118
Number of patients	117	118
Number of events	25	27

Treatment-Related AEs^a (≥10% in either arm)



CARCINOMES NASOPHARYNGES

ANTI PD1 MONOTHERAPIE

PATIENTS PRE TRAITES PAR PLATINE

PHASE III KN 122 Chan et al., ESMO 2021

59^e CONGRÈS
SFCCF 2021



- Pas de bénéfice au Pembro vs Chimio en terme de SG, SSP, Taux de réponse
- Bénéfice en termes d'effets secondaires
- Bénéfices dans certains sous groupes ?
 - Dans cette étude, CPS < 10,
 - Autres études: charges tumorales – élevées (LDH, charge plasmatique EBV), 1 ligne précédente vs > 1 ligne

CARCINOMES NASOPHARYNGES

ANTI PD1 COMBO CHIMIO 1^{ère} LIGNE R/M

JUPITER 02 Xu et al., ASCO 2021



JUPITER-02: Study Design


(ClinicalTrials.gov Identifier: NCT03581786)

Key Eligibility Criteria

- Primary metastatic NPC or recurrent NPC after curative-intent therapy
- Treatment naive for recurrent or metastatic (R/M) disease
- ECOG 0-1
- 18-75 yrs
- Measurable disease per RECIST v1.1

Stratification Factors

- Recurrent vs Primary metastatic
- ECOG PS 0 vs 1



• Primary endpoint: PFS by a blinded independent review committee (BIRC) per RECIST v1.1

• Secondary endpoints: PFS by the Investigator, ORR, DoR, DCR, OS, and PFS & OS 1-year and 2-year rates

© Genentech, Inc. All rights reserved. © 2021

For more information, please visit us at www.gilead.com or contact your local medical representative.

CARCINOMES NASOPHARYNGES

ANTI PD1 COMBO CHIMIO 1^{ère} LIGNE R/M

JUPITER 02 Xu et al., ASCO 2021


SFCCF 2021



9

Progression-Free Survival by BIRC per RECIST v1.1

Institution: Analysis Date: Oct 21, 2020



CARCINOMES NASOPHARYNGES

ANTI PD1 COMBO CHIMIO 1^{ère} LIGNE R/M

JUPITER 02 Xu et al., ASCO 2021



SFCCF 2021

Response and Duration of Response by BIRC per RECIST v1.1

Characteristic (%)	Toripalimab + GP (N=146)	Placebo + GP (N=143)
Objective Response Rate ^a	77.4	68.4
95% CI	(71.6, 83.9)	(58.1, 74.1)
P value	0.0335	
Best Overall Response ^a		
Complete Response	19.2	11.2
Partial Response	58.2	55.2
Stable Disease	10.3	13.3
Progressive Disease	3.1	5.6
Not evaluable	6.2	5.6
Non-CK/Non-P11 ^b	2.7	3.4
No evidence of disease ^c	0	0.7
Median DuR, (95%CI), months	10.0 (8.8, NE)	5.7 (5.4, 6.8)
IIR (95%CI)	0.50 (0.53-0.73)	
P value	0.0014	

^a All the best overall responses.
^b Non-CK/Non-P11 includes subjects who did not have a pathologic assessment by IHC.
^c No evidence of disease included subjects who had a pathologic assessment by IHC.


CARCINOMES NASOPHARYNGES

ANTI PD1 COMBO CHIMIO 1^{ère} LIGNE R/M

JUPITER 02 Xu et al., ASCO 2021



Progression Free Survival by BIRC in Key Subgroups



CARCINOMES NASOPHARYNGES

ANTI PD1 COMBO CHIMIO 1^{ère} LIGNE R/M

JUPITER 02 Xu et al., ASCO 2021

SFCCF 2021



Overall Survival Update

Three-month OS update after PFE Interim Analysis on Feb 15, 2021

